Two polio vaccines are used against the paralytic disease polio. The first, developed by Jonas Salk, consists of inactivated poliovirus. Based on three wild virulent strains, inactivated using formalin, it is administered by injection and is very safe. It confers IgG-mediated immunity, which prevents poliovirus from entering the bloodstream and protects the motor neurons, eliminating the risk of bulbar polio and post-polio syndrome. The second, developed by Albert Sabin, originally consisted of three live virus strains, attenuated by growth in cell culture. Since 2016, only two strains have generally been included. They contain multiple mutations, preventing them from replicating in the nervous system. The Sabin vaccine stimulates both antibodies and cell-mediated immunity, providing longer-lasting immunity than the Salk vaccine. It can be administered orally, making it more suitable for mass vaccination campaigns. In around three cases per million doses, the live vaccine reverts to a virulent form and causes paralysis. Vaccination has reduced the number of wild-type polio cases from around 350,000 in 1988 to just 33 in 2018, and eradicated the disease from most countries.